Interview with Darren Ji, CEO, PharmaLegacy
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
Address: Building 7, 388 Jialilue Rd.,Zhangjiang High-Tech Park, Shanghai,China
Tel: (86) 21-6100 2280
Web: http://www.pharmalegacy.com/Home.aspx?lang=en
PharmaLegacy Laboratories is a leading preclinical Contract Research Organization (CRO) providing specialty pharmacology services in Bone Metabolism, Immune Diseases, Inflammation, Oncology, and Orthopaedics and Tissue Engineering. The core competency of PharmaLegacy stems from our pioneering work and expertise in developing and running specialized animal models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. We also conduct adjacency studies in PK/PD, molecular pharmacology and preliminary toxicology. Overall we provide one-stop shopping of preclinical pharmacology services for early proof of concept of therapeutics and fulfillment of regulatory requirement.
Aspiring to collaborate with our global clients to accelerate their missions to develop new therapies, PharmaLegacy provides quality services with faster turnaround and higher productivity of R&D to IND/IDE endeavors for pharmaceutical, biotech, and orthopaedic device companies around the world.
The PharmaLegacy management team consists of world-renowned scholars, top service scientists and seasoned business leaders from the US and Shanghai. We have fully established animal pharmacology models of rodents, rabbits, dogs, sheep, goats and non-human primates which are used to serve our current clients of large multinational pharmaceutical and medical device companies, as well as small- to-medium-sized biotech companies.
Research
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
Dr CJ Wang, CEO of Frontier Biotech, shares his exciting ten-year journey with Frontier and their distinctive focus on HIV drug development, with their flagship compound, Aikening®, launched in China…
Dr Laura Benjamin, CEO of Oncologie, shares the rationale behind their exceptional decision to simultaneously establish offices in both the US and China; their unique biomarker approach focusing on the…
Shirley Xu, president of Baxter Greater China, reflects on her extraordinary 26-year (and counting) career with Baxter China, including her perspectives on the success factors behind Baxter’s growth in the…
John Moller, CEO; and Yooni Kim, executive director of Asia operations, for Novotech, share the competitive positioning of Novotech as a full-service CRO for biotech companies interested in the Asia-Pacific…
China’s roll-out of a 25-province expansion to the 4+7 pilot procurement scheme has seen pharma companies scrambling to cut prices for their drugs even further in the latest bidding war.…
Kevin Pan, CEO of Asieris, shares the origins behind the company’s distinctive name and how it reflects their ambition to bridge scientific discoveries and innovative medicines; their focus on genitourinary…
Dr Irwin Wang, CEO of Reistone Biopharma, shares her motivations behind the establishment of the company, their extremely productive collaboration with Jiangsu Hengrui (China’s largest pharma company by market capitalization),…
Geoff Kau, Co-GM and CSO of Ping An Smart City, introduces the breathtaking breadth of the Ping An healthcare ecosystem, and the interesting projects his subsidiary, Ping An Smart City,…
Charles Bark, CEO and founder of HiNounou, shares the touching personal story of what inspired him to establish HiNounou as a complete remote healthcare solution package for elderly people; how…
China-born entrepreneurs are returning to their homeland to find an industry filled with incentives in place for innovation, independent of generics. Here, we highlight five unique biotechs looking to serve…
An exclusive interview with Jason Smith, SVP (Asia Pacific, Middle East and Africa); Gerry Muhle, VP (International Medical Aesthetics); and White Wang, China President, of Allergan, at the inauguration ceremony…
Wang Wei of Winhealth Pharma, one of China’s leading contract development and commercialisation organisations, outlines the rationale behind the company’s formation, how its business model is changing to keep up…
See our Cookie Privacy Policy Here
